N/A
Manufactured by Janssen Pharmaceuticals, Inc.
13,486 FDA adverse event reports analyzed
Last updated: 2026-04-15
PENTOSAN POLYSULFATE SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Janssen Pharmaceuticals, Inc.. The most commonly reported adverse reactions for PENTOSAN POLYSULFATE SODIUM include MACULOPATHY, OFF LABEL USE, RETINAL PIGMENTATION, DRY AGE-RELATED MACULAR DEGENERATION, PIGMENTARY MACULOPATHY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PENTOSAN POLYSULFATE SODIUM.
This profile reflects 13,486 FDA FAERS reports that mention PENTOSAN POLYSULFATE SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include MACULOPATHY, OFF LABEL USE, RETINAL PIGMENTATION, DRY AGE-RELATED MACULAR DEGENERATION, PIGMENTARY MACULOPATHY, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Janssen Pharmaceuticals, Inc. in connection with PENTOSAN POLYSULFATE SODIUM. Always verify the specific product and NDC with your pharmacist.